Liquidia Bought Peace for $380 Million — and Sold Its Growth Story to Pay for It
YUTREPIA grows 31% to $222.7M, but the label narrows to PAH, the 2027 billion-dollar refrain goes quiet, and L606 inherits the PH-ILD future
LQDA · Earnings Call · 2026-11-10
The Bill for Certainty
Liquidia spent the quarter buying the one thing a single-asset biotech can never manufacture: the end of a lawsuit. The price was explicit, and it is the reason a company that produced record adjusted EBITDA of $140.5M and $222.7M of net product sales reported a GAAP net loss of $236.3M. A one-time settlement charge of $389.7M — $380.7M of it cash, payable through April 2027 — landed on the P&L. Strip it out and the operating machine is genuinely impressive. Net product sales for PH ILD and PAH patients on YUTREPIA rose $52M sequentially, with $212.2M of it true paid-patient demand rather than channel fill. Gross margin held near 94%. Selling costs stayed flat in dollars while falling from 33% to 26% of revenue. Cash built to $396.1M before the settlement payments. “We have no need to raise extra capital and we are not changing our operating plan.” — Michael Kaseta, Chief Operating Officer and Chief Financial Officer · 2026-11-10 The tape has already arbitrated the event twice. Shares peaked at $91.03 on 2026-08-10, then fell 62% in nine trading days around the late-September ruling, then rallied 93% over the last four weeks on the settlement — and still sit 43.5% below that high. The market has priced "survival confirmed, growth de-rated." The valuation reset is brutal in relative terms: price-to-revenue has compressed to 15.8x from 88.9x a year ago.The Label Got Narrower — and the Growth Story Moved With It
Here is the sentence that reframes the entire equity story, delivered almost as an aside: “PAH has been the core of that growth. From launch through the end of September, more than 60% of the prescriptions included a PAH diagnosis and in the month of September, it rose to over 70%.” — Roger Jeffs, Chief Executive Officer · 2026-11-10 The company now promotes into pulmonary arterial hypertension, and roughly 80% of the ~$4.9B U.S. branded prostacyclin market sits there anyway — 25,000 patients on therapy, of whom YUTREPIA has a small slice. But compare that to what management spent the last year selling. In March, the Chief Commercial Officer described PH-ILD as “definitely the bigger opportunity long term” — Scott Moomaw, Unknown · 2026-03-05 — the white space thesis that justified a sales force expansion, a 50/50 script mix, and a revenue trajectory aimed at a billion dollars. That space is now structurally frozen: existing PH-ILD patients may stay on drug, but no new ones can be promoted. October's referral rate — “more than 75% of the daily rate in Q3” — Roger Jeffs, Chief Executive Officer · 2026-11-10 — is being framed as a "floor." A 25% step-down in referral velocity is a floor only if you believe the competitor's "Dear healthcare provider" letter, not the label, caused it. The keyword record captures the pivot cleanly. The litigation vocabulary that dominated prior quarters — range of outcomes, royalties, injunctions — has vanished from the top of the list. In its place: settlement offer, phenotype, ultimate adjudicator. Management is no longer litigating; it is litigating the definition of the patient, arguing through its Chief Medical Officer that right-heart-catheterized Group 1 disease is the prescriber's call. That is a subtle, necessary retreat.What Management Stopped Saying
The most telling absence is the number. For at least three consecutive calls, the billion-dollar-2027 marker was repeated with confidence — in August, “we believe we'll be more than $1 billion in sales in 2027” — Michael Kaseta, Chief Operating Officer and Chief Financial Officer · 2026-08-12 — a target originally set when PH-ILD was a growth engine and the trial was unresolved. Yesterday, asked directly about a 2027 outlook: “we're very much a data-driven company. We'd like to see a little more data before putting any guidance out related to 2027.” — Michael Kaseta, Chief Operating Officer and Chief Financial Officer · 2026-11-10 That is a disciplined answer, and it is also a retreat from a public commitment. Roger Jeffs names the mood himself: “for some investors, Liquidia is now a show-me story.” — Roger Jeffs, Chief Executive Officer · 2026-11-10That disclosure matters more than the headline charge. It explains why management let a ruling play out rather than capitulate — and it tells you the entire PH-ILD revenue base was, for a moment, on the negotiating table. Paying $380.7M in cash to keep it is defensible arithmetic; calling the alternative "grossly misleading" is the sound of a company that knows it got the better end of a bad hand.They wanted 100% of PH-ILD revenue through 2042 so through the expiry of the patent... And they also wanted 50% of the non-infringing PAH revenue.